← Back to Search

Gene Therapy

AGT103-T for HIV/AIDS

Phase 1
Waitlist Available
Research Sponsored by American Gene Technologies International Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up days 1 to 180 post-infusion
Awards & highlights

Summary

This trial tests a new treatment where a patient's own immune cells are modified to better fight HIV. It targets people with HIV who have their virus under control with medication.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~days 1 to 180 post-infusion
This trial's timeline: 3 weeks for screening, Varies for treatment, and days 1 to 180 post-infusion for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Assess the safety of AGT103-T in HIV+ participants with well-controlled viremia on antiretroviral therapy: adverse events

Trial Design

2Treatment groups
Experimental Treatment
Group I: Low Dose CohortExperimental Treatment1 Intervention
A single infusion of ≥1x10e8 and <1x10e9 genetically modified T cells.
Group II: High Dose CohortExperimental Treatment1 Intervention
A single infusion of ≥1x10e9 and <5x10e9 genetically modified T cells.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
AGT103-T
2020
Completed Phase 1
~10

Find a Location

Who is running the clinical trial?

American Gene Technologies International Inc.Lead Sponsor
3 Previous Clinical Trials
38 Total Patients Enrolled
~1 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top